TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05874609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching with VR spine simulator
Description: The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional didactic teaching
Description: A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
Study: NCT05612009

Intervention type: COMBINATION_PRODUCT
Intervention: Toothpastes
Description: Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride).

Intervention type: COMBINATION_PRODUCT
Intervention: Toothpastes
Description: Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride).
Study: NCT06441214

Intervention type: DRUG
Intervention: Zanubrutinib
Description: Patients will be treated with Zanubrutinib as per routine clinical practice.
Study: NCT05749315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Play Based Therapy
Description: Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Communication Training
Description: Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
Study: NCT05846373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic Acid 500 MG Extended Release Oral Tablet
Description: Nicotinic acid 500 mg for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic Acid 1000 MG Extended Release Oral Tablet
Description: Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
Study: NCT05613023

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study: NCT05994027

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ATTACH™ Online Platform Parenting Program
Description: ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
Study: NCT04921228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: * 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV
Study: NCT06029569

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Rapamycin drug balloon angioplasty
Description: Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapamycin drug balloon angioplasty
Description: Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Paclitaxel drug balloon angioplasty
Description: Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug balloon angioplasty
Description: Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
Study: NCT04767503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Desflurane
Description: Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
Study: NCT05481489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: Atropine Sulfate 0.05% Ophthalmic Solution
Study: NCT05633888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CATAMARAN SI Joint Fusion System
Description: Placement of the Catamaran Fixation Device
Study: NCT04826939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFDx device and leva device
Description: Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
Study: NCT04958174

Intervention type: DEVICE
Intervention: web-application
Description: web application for monitoring children's development
Study: NCT06153537

Intervention type: DRUG
Intervention: Insulin degludec
Description: Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
Study: NCT05235542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Oral,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV infusion,Specified dose on specified days
Study: NCT05977062

Intervention type: OTHER
Group type: OTHER
Intervention: Self screening
Description: Score ISI (Index de Sévérité de l'Insomnie)
Study: NCT05009758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal mucosa mRNA sampling
Description: Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
Study: NCT05977062

Intervention type: OTHER
Group type: OTHER
Intervention: Phone call
Description: Phone call at the beginning of the program and at the middle and at the end.

Intervention type: OTHER
Group type: OTHER
Intervention: Online questionnaires
Description: To be completed at week 1, 6, 12 and 24.
Study: NCT05152771

Intervention type: OTHER
Group type: OTHER
Intervention: KETOGENIC DIET
Description: This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers.
Study: NCT05137769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
Study: NCT05875298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy protocol
Description: the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy protocol and medical drugs
Description: the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical drugs
Description: The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical drugs
Description: The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
Study: NCT06189924

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic analysis of exhaled breath condensate
Description: Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic analysis of exhaled breath condensate
Description: Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.
Study: NCT05009758

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
Study: NCT06087484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)
Description: The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
Study: NCT05009758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical history of patients, demographic data, concomitant medication, questionnaire
Description: Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
Study: NCT05836168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omnibiotic Stress Repair
Description: multispecies probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06175052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
Study: NCT05479240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
Study: NCT05084118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Landiolol HCl
Description: continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
Study: NCT05479240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-range radiotherapy
Description: 5\*5Gy，d1-d5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-range radiotherapy
Description: 5\*5Gy，d1-d5
Study: NCT05860738

Intervention type: OTHER
Intervention: sterilization
Description: autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).

Intervention type: OTHER
Intervention: sterilization
Description: autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
Study: NCT05392868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KNO3
Description: 5% potassium nitrate solution
Study: NCT05192460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neoantigen tumor vaccine with or without PD-1/L1
Description: In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
Study: NCT05084118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: continous application of isotone saline solution for 72 hours
Study: NCT06051903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization wih movement
Description: The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization wih movement
Description: The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
Study: NCT05741398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR system by Demaod
Description: non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
Study: NCT05549791

Intervention type: DRUG
Intervention: Remimazolam Tosilate for Injection
Description: Remimazolam Tosilate for Injection

Intervention type: DRUG
Intervention: Remimazolam Tosilate for Injection
Description: Remimazolam Tosilate for Injection
Study: NCT04294030

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx HSV-2 Test
Description: For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx HSV-2 Test
Description: For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx HSV-2 Test
Description: For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx HSV-2 Test
Description: For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
Study: NCT06140966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by vein: days 1-4 of each Induction cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Given by vein: days 1-4 of each Induction cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein: days 1-4 of each Induction cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given by vein: days 1-4 of each Induction cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by vein: day -1 of Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: day 0 of Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
Study: NCT05645965

Intervention type: DEVICE
Intervention: ICD insertion
Description: Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
Study: NCT05388617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brera
Description: The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brera
Description: The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.